AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Anduril explores Israeli expansion as defense-tech boom accelerates
2
Amdocs’ layoffs fail to halt share slide
3
Marvell CTO: "The market has finally reached the bottleneck we solve"
4
Germany’s missile search draws attention to secretive Israeli startup Covenant
5
Unicorn Artlist to cut 200 jobs, 40% of workforce, despite surpassing $300 million ARR
More news

Richard Francis

6 stories about Richard Francis
בניין חברת טבע כפר סבא

The deal that signals Teva is back

30.04.26|Sophie Shulman
A calculated biotech acquisition and strong earnings revive confidence in the pharma giant.
ריצ'רד פרנסיס מפגש העיתונאים

Teva CEO cashes in $30 million in shares in two weeks

08.03.26|Sophie Shulman
Richard Francis sells stock after Teva’s 110% rally over the past year.
נשיא ומנכ"ל טבע ריצ'רד פרנסיס

After a threefold rally, Teva faces its next test

29.01.26|Sophie Shulman
Innovative drugs surge, but 2026 forecasts revive investor doubts.
מטה טבע כפר סבא

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory